Related Experiment Video

Updated: Jul 16, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Patient concern regarding bleeding side effects from oral anticoagulation therapy for atrial fibrillation: an

Ikuko Ueda1, Shun Kohsaka1, Nobuhiro Ikemura1

  • 1Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinju-ku, Tokyo 1608582, Japan.

European Journal of Cardiovascular Nursing
|September 11, 2023
PubMed

Insights

Nearly one-third of patients with atrial fibrillation (AF) taking anticoagulants worry about bleeding risks. This concern persists long-term, impacting quality of life for many individuals on anticoagulant therapy.

Area of Science:

  • Cardiology
  • Patient-Reported Outcomes
  • Pharmacology

Background:

  • Atrial fibrillation (AF) management frequently involves oral anticoagulants (OACs).
  • Patient concerns regarding bleeding side effects can influence treatment adherence and quality of life.
  • Understanding the prevalence of these concerns is crucial for optimizing patient care.

Purpose of the Study:

  • To quantify the percentage of patients with AF who express concern about bleeding side effects from anticoagulant medications.
  • To explore demographic and clinical factors associated with bleeding concerns in AF patients.

Main Methods:

  • A prospective study enrolled 3312 patients with AF for management.
  • Patient-reported outcomes were assessed using the Atrial Fibrillation Effect on Quality-of-life (AFEQT) questionnaire.
  • Patients were categorized into 'OAC concern' or 'no OAC concern' groups based on their responses regarding bleeding side effects.

Main Results:

  • At baseline, 29.3% of patients on oral anticoagulants reported concern about bleeding side effects.
  • Women and patients experiencing AF-related symptoms were more likely to be concerned about bleeding.
  • At 1-year follow-up, 41.6% of patients remained concerned about bleeding risks.

Conclusions:

  • A significant proportion of patients with AF on anticoagulant therapy experience concern regarding bleeding.
  • These concerns are present both in the short-term and long-term management of anticoagulation.
  • Addressing patient-reported bleeding concerns is essential in AF management.
Abstract

Keywords:
AnticoagulationAtrial fibrillationBleeding side effectsPatient perception

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.7K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.7K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
747
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
987
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
559